Differential Response to Sorafenib Administration for Advanced Hepatocellular Carcinoma

Sorafenib has been used to treat advanced hepatocellular carcinoma (aHCC). However, there is no evidence for a response of different target lesions to sorafenib administration. Therefore, we aimed to evaluate the effect of sorafenib on various aHCC target lesions. The outcomes of sorafenib treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Song-Fong, Chong, Sio-Wai, Huang, Chun-Wei, Hsu, Heng-Yuan, Pan, Kuang-Tse, Hung, Chien-Fu, Wu, Tsung-Han, Lee, Chao-Wei, Hsieh, Chia-Hsun, Wang, Ching-Ting, Chai, Pei-Mei, Yu, Ming-Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496215/
https://www.ncbi.nlm.nih.gov/pubmed/36140381
http://dx.doi.org/10.3390/biomedicines10092277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496215/
https://www.ncbi.nlm.nih.gov/pubmed/36140381
http://dx.doi.org/10.3390/biomedicines10092277

Ejemplares similares